Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

This looks modestly favorable on design alone. The study is placebo-controlled in a well-defined CRSwNP population, and the primary endpoint—change from baseline in nasal polyp score at Week 24—is standard, clinically interpretable, and directly tied to disease burden. A 24-week treatment window is usually sufficient to detect a biologic effect in polyp disease, so the endpoint timing is not obviously too short. The protocol also appears aimed at dose finding, which can improve odds that at least one regimen shows signal, but it also introduces multiplicity and sample-splitting risk that can blur the headline result. The biggest handicap is the absence of disclosed mechanism or prior efficacy data in the trial fields; without that, this should not be treated like a de-risked asset. Phase 2 readouts are inherently volatile, and the trial is slightly past estimated primary completion while still listed active-not-recruiting, creating some disclosure-timing risk but not clear failure evidence. Overall, the setup supports a better-than-even chance of positivity, but only by a moderate margin.

SHR-1905 is a humanized anti-TSLP monoclonal antibody with validated mechanism in CRSwNP. Tezepelumab, another anti-TSLP, achieved highly significant NPS reductions in the Phase 3 WAYPOINT trial (NPS -2.07 vs placebo, p<0.0001), confirming TSLP blockade is effective in this indication. SHR-1905 demonstrated good safety and a long half-life (83-106 days) in Phase 1, and GSK's $1B+ acquisition of ex-China rights signals strong molecular confidence. As a Phase 2 dose-finding study in a well-characterized indication with validated endpoints, base rates for biologics with proven mechanism are favorable (~55-65%). The 24-week NPS endpoint is standard and well-powered for this class. However, uncertainty remains around optimal dosing, the specific patient population enrolled in China, and the lack of any efficacy signal in CRSwNP specifically for this molecule. The trial is ~60 days past estimated primary completion with no disclosed results, which is neutral. Competing biologics' success raises the bar but also confirms the target.

This Phase 2 trial evaluates SHR-1905, a biologic injection for chronic rhinosinusitis with nasal polyps (CRSwNP). The primary endpoint is change in nasal polyp score at Week 24, which is an objective, clinically validated measure. CRSwNP is a well-established indication with unmet need, and biologic therapies have demonstrated efficacy in this space (e.g., dupilumab). Hengrui is a major Chinese pharma with resources for execution. However, Phase 2 trials carry inherent uncertainty with roughly 50-60% failure rates for efficacy. The trial is past primary completion date (-60 days), suggesting data may be maturing. Given the objective endpoint, therapeutic area precedent, but early-phase risk, intrinsic probability slightly exceeds even odds but with meaningful uncertainty.

This is a Phase 2 trial for a monoclonal antibody (SHR-1905) in CRSwNP, a competitive space with established anti-IL4Rα therapies like dupilumab. The primary endpoint is the standard change in Nasal Polyp Score at Week 24, which is appropriate. The trial is past its primary completion date and is 'Active Not Recruiting', suggesting data collection is complete. However, the sponsor is a Chinese biopharma (Hengrui) with less established global regulatory track record for novel biologics in this indication. No prior Phase 2 data for SHR-1905 in CRSwNP is mentioned, introducing uncertainty about its efficacy profile relative to incumbents. The study also aims to explore dosage, which could indicate the primary analysis might be more complex than a simple dose-confirmation. Operational execution risk appears low given trial completion, but disclosure and data interpretation risk from a first major readout is moderate.

Trial design is solid: randomized, placebo-controlled Phase 2 evaluating SHR-1905 (anti-TSLP mAb) vs placebo in CRSwNP patients, with standard primary endpoint of NPS change from baseline at Week 24, a validated, objective measure sensitive to biologics (e.g., dupilumab's -1.89 vs placebo -0.17). Patient population is appropriate—chronic rhinosinusitis with nasal polyps, often Th2/eosinophil-driven, where upstream TSLP inhibition should yield benefit, as TSLP initiates allergic cascades. No prior clinical data disclosed, but mechanism aligns with successful biologics like Dupixent (IL4/13) and omalizumab (IgE); Phase 2 success in CRSwNP biologics ~60-70%. Sponsor Hengrui (600276.SH) has execution track record in respiratory/immunology. Dose-exploration supports positivity if any arm succeeds. Operational risks low: NCT05891483 active not recruiting, but primary completion overdue by 60 days (est Feb 2026, asOf Apr 2026), suggesting data collection complete, analysis pending—minimal execution delay risk. Disclosure risk moderate: Chinese sponsor may delay top-line, but endpoint clarity reduces ambiguity. Overall, favorable odds for statistical significance on NPS.

This Phase 2 trial for SHR-1905 in Chronic Rhinosinusitis with Nasal Polyps has a favorable probability of success. The indication has a clinically validated pathway, with biologics like dupilumab establishing strong efficacy benchmarks using similar co-primary endpoints (NPS and congestion). The primary completion date passed ~60 days ago, and the 'Active Not Recruiting' status suggests the study executed fully without operational termination. Hengrui is a sophisticated sponsor with resources to properly conduct this trial. However, confidence is tempered by the lack of disclosed Phase 1 data or mechanism of action details in the provided facts, introducing uncertainty about the molecule's specific pharmacodynamic profile. While the therapeutic area and endpoint selection are conducive to positive outcomes, the inherent risk of novel drug candidates in Phase 2 remains substantial. Overall, the trial design and context support a modestly positive outlook.

SHR-1905 is a novel biologic for CRSwNP, an indication with established precedent for anti-IL-5/IL-4 pathway success (dupilumab, mepolizumab). The Phase 2 design with NPS primary endpoint at 24 weeks is standard and well-validated. Hengrui is an experienced Chinese sponsor with proven execution capability. The trial completed primary completion 60 days ago (Feb 2026), suggesting data lock and analysis are underway. No early termination or safety signals disclosed. The placebo-controlled design with objective endpoint reduces placebo response risk. Primary concern: Chinese-only trial may have regulatory/commercial translation questions, but for binary efficacy readout this is less relevant. Prior Phase 1 data in asthma showed favorable PK/PD. Disclosure risk is moderate—Hengrui typically announces via ASH/ATS or press releases.

The intrinsic probability of a positive outcome for this Phase 2 trial of SHR-1905 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is very high, estimated at 85%. First, the therapeutic mechanism of thymic stromal lymphopoietin (TSLP) inhibition is exceptionally well-validated for this specific indication. Recently, AstraZeneca and Amgen's tezepelumab demonstrated overwhelmingly positive results in the Phase 3 WAYPOINT trial, driving significant reductions in the Nasal Polyp Score (NPS), nearly eliminating the need for subsequent surgery, and leading to FDA approval for CRSwNP. Second, SHR-1905, an optimized monoclonal antibody developed by Guangdong Hengrui and partnered with GSK, has already demonstrated strong target engagement, a favorable safety profile, and robust suppression of type 2 inflammatory biomarkers (e.g., eosinophils, FeNO) in Phase 1 testing. The Phase 2 primary endpoint—change from baseline in NPS at Week 24—is the standard regulatory benchmark for CRSwNP and has been consistently achieved by other upstream biologics like dupilumab and tezepelumab. Given Hengrui's operational competence, the clear mechanistic rationale, and the robust validation of anti-TSLP therapy in the exact same patient population and endpoint, the risk of a true efficacy failure is very low. Thus, a positive readout is highly anticipated.

The trial is in Phase 2, evaluating the efficacy and safety of SHR-1905 Injection in patients with Chronic Rhinosinusitis With Nasal Polyps. The primary endpoint is nasal polyp scores (NPS) at Week 24. Given that the study is active and not recruiting, it implies the trial is ongoing and likely has not yet reported results. The sponsor, Guangdong Hengrui Pharmaceutical Co., Ltd, is a credible entity with a vested interest in a positive outcome. While specific efficacy data is not provided, the trial's design and focus on a significant medical need suggest a potentially positive outcome.